Solasia Pharma K.K. Logo

Solasia Pharma K.K.

In-licenses and commercializes oncology treatments and supportive care products in Asia.

4597 | T

Overview

Corporate Details

ISIN(s):
JP3436500007
LEI:
Country:
Japan
Address:
港区芝公園二丁目11番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Solasia Pharma K.K. is a specialty pharmaceutical company focused on developing and commercializing innovative oncology products to address unmet medical needs in Japan and other Asian countries. The company's business model centers on in-licensing promising drug candidates and medical devices, primarily from the US and Europe. Its portfolio includes approved therapies for cancer treatment, such as Peripheral T-Cell Lymphoma, and supportive care solutions for managing treatment side effects like chemotherapy-induced nausea and vomiting (CINV) and oral mucositis. Solasia's development pipeline targets conditions including colorectal cancer and chemotherapy-induced peripheral neuropathy. The company leverages its small, expert team for quick and flexible decision-making to efficiently bring new treatments to market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-13 08:43
Report Publication Announcement
確認書
Japanese 8.1 KB
2025-08-13 08:42
Interim Report
半期報告書-第18期(2025/01/01-2025/12/31)
Japanese 228.0 KB
2025-03-31 08:49
Registration Form
訂正有価証券届出書(組込方式)
Japanese 147.2 KB
2025-03-31 08:43
Post-Annual General Meeting Information
臨時報告書
Japanese 23.8 KB
2025-03-26 07:30
Registration Form
訂正有価証券届出書(組込方式)
Japanese 181.4 KB
2025-03-26 07:21
Governance Information
内部統制報告書-第17期(2024/01/01-2024/12/31)
Japanese 22.7 KB
2025-03-26 07:20
Registration Form
確認書
Japanese 8.1 KB
2025-03-26 07:19
Annual Report
有価証券報告書-第17期(2024/01/01-2024/12/31)
Japanese 1.1 MB
2025-03-24 07:37
Registration Form
有価証券届出書(組込方式)
Japanese 263.8 KB
2025-03-10 07:31
Regulatory News Service
臨時報告書
Japanese 19.5 KB
2024-08-14 08:43
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-08-14 08:42
Interim Report
半期報告書-第17期(2024/01/01-2024/12/31)
Japanese 238.4 KB
2024-05-15 08:42
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-05-15 08:40
Quarterly Report
四半期報告書-第17期第1四半期(2024/01/01-2024/03/31)
Japanese 219.9 KB
2024-03-26 07:08
Post-Annual General Meeting Information
臨時報告書
Japanese 22.8 KB

Automate Your Workflow. Get a real-time feed of all Solasia Pharma K.K. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Solasia Pharma K.K.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Solasia Pharma K.K. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.